Moderna’s mRNA Flu Vaccine Outperforms Standard-Dose Flu Shot in Phase 3 Trial

A new Phase 3 trial published in the New England Journal of Medicine reported that Moderna’s investigational seasonal influenza vaccine, mRNA-1010, was superior to standard-dose licensed flu vaccines in adults aged 50 and older. In the per-protocol analysis, influenza-like illness occurred in 2.0% of mRNA-1010 recipients compared with 2.8% of standard-dose vaccine recipients, corresponding to 26.6% relative vaccine efficacy.

Seasonal flu remains difficult to control because influenza viruses change frequently, and vaccine effectiveness can vary by season and age group. mRNA vaccine technology may allow faster strain updates and more flexible manufacturing, although regulatory review and comparison with high-dose or adjuvanted vaccines remain important questions.

Yes2Vaccines message: mRNA technology may help modernize flu prevention, especially for older adults who remain at higher risk.